Use of directed evolution of mammalian cytochromes P450 for investigating the molecular basis of enzyme function and generating novel biocatalysts

被引:31
作者
Kumar, S [1 ]
Halpert, JR [1 ]
机构
[1] Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA
关键词
cytochrome P450; P450; directed evolution; random mutagenesis; biocatalysts;
D O I
10.1016/j.bbrc.2005.08.080
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Directed evolution has been successfully applied to the design of industrial biocatalysts for enhanced catalytic efficiency and stability, and for examining the molecular basis of enzyme function. Xenobiotic-metabolizing mammalian cytochromes P450 with their catalytic versatility and broad substrate specificity offer the possibility of widespread applications in industrial synthesis, medicine, and bioremediation. However, the requirement for NADPH-cytochrome P450 reductase, often cytoebrome b(5), and an expensive cofactor, NADPH, complicates the design of mammalian P450 enzymes as biocatalysts. Recently, Guengerich and colleagues have successfully performed directed evolution of P450s 1A2 and 2A6 initially by using colony-based colorimetric and genotoxicity screening assays, respectively, followed by in vitro fluorescence-based activity screening assays. More recently, our laboratory has developed a fluorescence-based in vitro activity screening assay system for enhanced catalytic activity of P450s 2131 and 3A4. The studies indicate an important role of amino acid residues Outside of the active site, which would be difficult to target by other methods. The approach can now be expanded to design these as well as new P450s using more targeted substrates of environmental, industrial, and medical importance. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:456 / 464
页数:9
相关论文
共 73 条
[1]   Colorimetric high-throughput assay for alkene epoxidation catalyzed by cytochrome P450BM-3 variant 139-3 [J].
Alcalde, M ;
Farinas, ET ;
Arnold, FH .
JOURNAL OF BIOMOLECULAR SCREENING, 2004, 9 (02) :141-146
[2]   Origins, current status, and future challenges of green chemistry [J].
Anastas, PT ;
Kirchhoff, MM .
ACCOUNTS OF CHEMICAL RESEARCH, 2002, 35 (09) :686-694
[3]   Cytochromes P450 and metabolism of xenobiotics [J].
Anzenbacher, P ;
Anzenbacherová, E .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2001, 58 (5-6) :737-747
[4]   How enzymes adapt: lessons from directed evolution [J].
Arnold, FH ;
Wintrode, PL ;
Miyazaki, K ;
Gershenson, A .
TRENDS IN BIOCHEMICAL SCIENCES, 2001, 26 (02) :100-106
[5]   High-throughput measurement of protein stability in microtiter plates [J].
Aucamp, JP ;
Cosme, AM ;
Lye, GJ ;
Dalby, PA .
BIOTECHNOLOGY AND BIOENGINEERING, 2005, 89 (05) :599-607
[6]  
Cali JJ, 2005, Proceedings of the 14th International Conference on Cytochromes P450: Biochemistry, Biophysics, and Bioinformatics, P77
[7]   Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: Identification of cytochrome P4502B enzymes and site-specific mutants with improved enzyme kinetics [J].
Chen, CS ;
Lin, JT ;
Goss, KA ;
He, YA ;
Halpert, JR ;
Waxman, DJ .
MOLECULAR PHARMACOLOGY, 2004, 65 (05) :1278-1285
[8]   Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer [J].
Chen, L ;
Waxman, DJ .
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (15) :1405-1416
[9]  
Cirino Patrick C, 2003, Methods Mol Biol, V231, P3
[10]  
Cirino Patrick C., 2003, V230, P117